By Mary A. Majumder, Christi J. Guerrini, Juli M. Bollinger, Robert Cook-Deegan, and Amy L. McGuire The 21st Century Cures Act was passed with support from both sides of the aisle (imagine that!) and signed into law by then-President Obama late last year. This ambitious legislation drives action in areas as diverse as drug and […]
By Rachel Sachs Today, President Trump signed an executive order (EO) whose purpose is ostensibly to reduce the regulatory burden imposed by the government on many different types of industries. The EO envisions achieving this goal through an incredibly sophisticated strategy: “for every one new regulation issued, at least two prior regulations be identified for […]
By Rachel Sachs Earlier this evening, the House of Representatives released the most recent draft of the 21st Century Cures Act. This is the fifth time I’ve blogged about the Act (prior posts here, here, here, and here), which has ballooned from a 200-page discussion draft in April 2015 to a 996-page draft version today. […]
By Nicholson Price The 21st Century Cures Act is a big deal; the House passed it handily, and we’re still waiting to see what the Senate does. A lot has been written about what it does in terms of changing FDA review processes, and a fair bit about the lovely increase in funding for NIH […]
By Rachel Sachs This morning, the House of Representatives passed the 21st Century Cures Act by a vote of 344-77, achieving a truly bipartisan result in a difficult political environment. (I’ve blogged about the Act several times now, and the House Energy & Commerce Committee has a clear section-by-section summary here.) There is much to […]
By Rachel Sachs Earlier today, the House Energy and Commerce Committee released the most recent draft of the 21st Century Cures Act, in time for it to be marked up by the Health Subcommittee tomorrow. At 300 pages, the new draft adds back in a number of provisions that were excised from the previous, 200-page […]
By Rachel Sachs Yesterday, a new discussion draft of the 21st Century Cures Act was released, just in time for today’s hearing on the draft before the House Energy and Commerce Committee. At just 200 pages (although with some sections still “to be supplied”), this version is just half the size of the previous draft. […]
By Rachel Sachs At the end of January, the House Energy & Commerce Committee released a discussion draft of the 21st Century Cures Act. This document marks the beginning of the legislative phase of the 21st Century Cures Initiative, during which the Committee has held numerous roundtables and hearings and issued several white papers. The […]
The common thread of our comments is the need to treat patients and physicians, not the data brokers, as the real stakeholders.
The past may hold important lessons for the future of health privacy for patients, physicians, and hospitals in the face of abortion subpoenas post-Dobbs.